NCT06660173 is a Phase 2 clinical trial of Maridebart Cafraglutide in Type 2 Diabetes Mellitus (T2DM), sponsored by Amgen.

Who is sponsoring NCT06660173?

NCT06660173 is sponsored by Amgen.

What drugs are being tested in NCT06660173?

Interventions in NCT06660173: Maridebart Cafraglutide, Placebo.

What condition does NCT06660173 study?

NCT06660173 studies Type 2 Diabetes Mellitus (T2DM).

Is NCT06660173 still recruiting?

NCT06660173 is currently active, enrolled. Last updated 25 November 2025.

Last reviewed 2025-11-25 · How we verify

NCT06660173

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Study of Maridebart Cafraglutide in Adult Participants With Type 2 Diabetes Mellitus (T2DM)

Active, enrolled Phase 2 Last updated 25 November 2025

What this trial tests

Phase 2 trial testing Maridebart Cafraglutide in Type 2 Diabetes Mellitus (T2DM) in 409 participants. Participants enrolled and being followed up; not accepting new ones.

Timeline

7 November 2024

Primary endpoint
6 October 2025

10 November 2026

Quick facts

Lead sponsor	Amgen
Phase	Phase 2
Status	Active, enrolled
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	double
Primary purpose	treatment
Enrollment	409
Start date	7 November 2024
Primary completion	6 October 2025
Estimated completion	10 November 2026
Sites	96 locations across Hong Kong, Italy, Japan, Greece, Austria, Sweden, Taiwan, Hungary

Drugs / interventions tested

Maridebart Cafraglutide — full drug profile →
Placebo

Conditions studied

Type 2 Diabetes Mellitus (T2DM) — all drugs for Type 2 Diabetes Mellitus (T2DM) →

Sponsor

Amgen — full company profile →

Who can join

18 and older, any sex, with Type 2 Diabetes Mellitus (T2DM). Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The main purpose of this study is to assess the dose-response relationship of maridebart cafraglutide on glucose control compared with placebo.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

An Overview of Existing and Emerging Weight-Loss Drugs to Target Obesity-Related Complications: Insights from Clinical Trials.
Kim MK, Kim HS. · · 2025 · cited 4× · PMID 39696983 · DOI 10.4062/biomolther.2024.228

Verify or expand the search:

Other trials of Maridebart Cafraglutide

Trials testing the same drug.

NCT07523711 — Effect of Maridebart Cafraglutide on How Oral Contraceptives Are Absorbed and Processed in the Body in Postmenopausal Fe · Phase 1 · not yet recruiting
NCT07313761 — A Trial to Compare the Extent to Which Maridebart Cafraglutide (AMG 133) is Made Available in the Body When Administered · Phase 1 · active not recruiting
NCT07229157 — Effect of Maridebart Cafraglutide on the Heart's Electrical Activity · Phase 1 · active not recruiting
NCT07226778 — Comparing the Extent to Which Maridebart Cafraglutide (AMG 133) is Made Available in the Body When Administered Using Tw · Phase 1 · active not recruiting
NCT07037433 — Evaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiov · Phase 3 · recruiting

Other recruiting trials for Type 2 Diabetes Mellitus (T2DM)

Currently open trials in the same condition.

NCT07533539 — Phase I Study to Evaluate the Pharmacokinetics and Safety After Co-administration of L03RD1 and L03RD2 or Administration · Phase 1 · recruiting
NCT07366775 — A Telenursing Program to Support Diabetes Self-Management · NA · active not recruiting
NCT07398495 — Multimodal Training Effects in Middle-Aged and Older Adults With Diabetic Sarcopenia · NA · recruiting
NCT07465224 — A Study to Evaluate ALN-4324 on Insulin Sensitivity in Adults With Type 2 Diabetes Mellitus · Phase 2 · recruiting
NCT07442006 — Glycemic Variability of Combination Therapies in T2DM · Phase 4 · recruiting

Other Amgen trials

Trials by the same sponsor.

NCT07223190 — A Study Evaluating Subcutaneous Versus Intravenous Blinatumomab in Newly Diagnosed Adults With B-cell Precursor Acute Ly · Phase 3 · not yet recruiting
NCT07493512 — Trial of Xaluritamig in Adults With Metastatic Castration-resistant Prostate Cancer · Phase 1 · not yet recruiting
NCT07531095 — Study of Tarlatamab + ZL-1310 +/- Anti-programmed Death Ligand 1 (Anti-PD-L1) in Small Cell Lung Cancer (SCLC) · Phase 1 · not yet recruiting
NCT06987539 — A Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Inebilizumab in Children With Gen · Phase 2 · recruiting
NCT05909761 — Observational Safety Study in Women With Neuromyelitis Optica Spectrum Disorder (NMOSD) Exposed to UPLIZNA® During Pregn · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06660173 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Amgen
Last refreshed: 25 November 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06660173.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing